Key facts
- Model Medicines’s last known valuation is $81.3M (Nov 2025).
- It has raised $18.8M across 4 recorded rounds; the latest was Seed Round ($3.3M) in Oct 2025.
- Notable investors include 8VC, BioTools Innovator, Irving Investors, Triton Funds, Thermopolis Partners — 8 tracked in total.
- Model Medicines has filed 4 Form Ds with the SEC since 2021, most recently Nov 2025 ($3.3M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Model Medicines
Funding rounds
4 roundsAbout Model Medicines
Developer of an artificial intelligence-driven drug discovery platform designed to accelerate the creation of life-changing drugs. The company offers a developed pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, gastric disorders, neurological disorders, and communicable diseases to develop drugs, enabling healthcare institutions to create better medicines tailored to patients' needs.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 13
- Website
- modelmedicines.com/
- Ownership
- Privately Held (backing)
Model Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Model Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Model Medicines in its N-PORT filings yet. We sweep new filings monthly.